Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International Journal of Biochemistry and Cell Biology

• Publication date

  2014-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.biocel.2014.07.017PMID 25084554
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological chaperones as therapeutics for lysosomal storage diseases.

  2013cited by this paper
• Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.

  2013cited by this paper
• Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase

  2013cited by this paper
• Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease.

  2012cited by this paper
• Non-iminosugar glucocerebrosidase small molecule chaperones.

  2012cited by this paper
• In situ synthesis of fluorescent membrane lipids (ceramides) using click chemistry

  2012cited by this paper
• Ex Vivo and in Vivo Effects of Isofagomine on Acid β-Glucosidase Variants and Substrate Levels in Gaucher Disease*

  2011cited by this paper
• Pharmacological chaperone therapy for Gaucher disease: a patent review

  2011cited by this paper
• Second‐Generation Iminoxylitol‐Based Pharmacological Chaperones for the Treatment of Gaucher Disease

  2011cited by this paper
• Computational Prediction of Structure-Activity Relationships for the Binding of Aminocyclitols to β-Glucocerebrosidase

  2011cited by this paper
• Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.

  2011cited by this paper
• X-ray and Biochemical Analysis of N370S Mutant Human Acid β-Glucosidase

  2010cited by this paper
• Click chemistry approach to new N-substituted aminocyclitols as potential pharmacological chaperones for Gaucher disease.

  2010cited by this paper
• The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β‐glucosidase

  2010cited by this paper
• Molecular Basis of Reduced Glucosylceramidase Activity in the Most Common Gaucher Disease Mutant, N370S

  2010cited by this paper
• Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease.

  2009cited by this paper
• Characterization of gene-activated human acid-β-glucosidase: Crystal structure, glycan composition, and internalization into macrophages

  2009cited by this paper
• Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics

  2009cited by this paper
• Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.

  2009cited by this paper
• Synthesis and biological properties of Pachastrissamine (jaspine B) and diastereoisomeric jaspines.

  2009cited by this paper
• Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.

  2009cited by this paper
• Q&A: What are pharmacological chaperones and why are they interesting?

  2009cited by this paper
• Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease*

  2009cited by this paper
• Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells.

  2009cited by this paper
• 6‐Amino‐6‐deoxy‐5,6‐di‐N‐(N′‐octyliminomethylidene)nojirimycin: Synthesis, Biological Evaluation, and Crystal Structure in Complex with Acid β‐Glucosidase

  2009cited by this paper
• Treatment perspectives for the lysosomal storage diseases

  2008cited by this paper
• An evolutionary and structure‐based docking model for glucocerebrosidase–saposin C and glucocerebrosidase–substrate interactions—Relevance for Gaucher disease

  2008cited by this paper
• Crystal Structures of Complexes of N-Butyl- and N-Nonyl-Deoxynojirimycin Bound to Acid β-Glucosidase

  2007cited by this paper
• Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease

  2007cited by this paper
• Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.

  2007cited by this paper
• Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.

  2007cited by this paper
• Accumulation of Glucosylceramide in Murine Testis, Caused by Inhibition of β-Glucosidase 2

  2007cited by this paper
• N4-phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease.

  2007cited by this paper
• Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease.

  2006cited by this paper
• Effective cell and gene therapy in a murine model of Gaucher disease

  2006cited by this paper
• The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms

  2006cited by this paper
• Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.

  2006cited by this paper
• AAV8‐mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease

  2006cited by this paper
• RNAi-mediated inhibition of the glucosylceramide synthase (GCS) gene: A preliminary study towards a therapeutic strategy for Gaucher disease and other glycosphingolipid storage diseases.

  2006cited by this paper
• Hydrophilic iminosugar active‐site‐specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients

  2006cited by this paper
• Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.

  2006cited by this paper
• Design and Synthesis of Highly Potent and Selective Pharmacological Chaperones for the Treatment of Gaucher's disease

  2006cited by this paper
• Scalable molecular dynamics with NAMD

  2005cited by this paper
• X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease.

  2005cited by this paper
• X-ray structure of human acid-beta-glucosidase covalently bound to conduritol B epoxide

  2005cited by this paper
• Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease.

  2005cited by this paper
• Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.

  2005cited by this paper
• Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles.

  2005cited by this paper
• New directions in the treatment of Gaucher disease.

  2004cited by this paper
• A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity.

  2003cited by this paper
• X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher disease

  2003cited by this paper
• Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease

  2002cited by this paper
• Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides†

  2001cited by this paper
• Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

  2000cited by this paper
• Intracellular transport of acid β‐glucosidase and lysosome‐associated membrane proteins is affected in Gaucher's disease (G202R mutation)

  1999cited by this paper
• Gaucher disease: gene frequencies and genotype/phenotype correlations.

  1997cited by this paper
• Hematologically important mutations: Gaucher disease.

  1997cited by this paper
• Prospective study of neurological responses to treatment with macrophage‐targeted glucocerebrosidase in patients with type 3 Gaucher's disease

  1997cited by this paper
• Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids

  1996cited by this paper
• VMD: visual molecular dynamics.

  1996cited by this paper
• An Effective Strategy for the Synthesis of 6-O-(2-Amino-2-deoxy-.alpha.-D-glucopyranosyl)-D-chiro- and -D-myo-inositol 1-Phosphate Related to Putative Insulin Mimetics

  1994cited by this paper
• Measurement of co‐localization of objects in dual‐colour confocal images

  1993cited by this paper
• Semianalytical treatment of solvation for molecular mechanics and dynamics

  1990cited by this paper
• A procedure for the rapid purification in high yield of human glucocerebrosidase using immunoaffinity chromatography with monoclonal antibodies.

  1986cited by this paper
• Comparison of simple potential functions for simulating liquid water

  1983cited by this paper
• Electronic Reprint Biological Crystallography Structural Comparison of Differently Glycosylated Forms of Acid-¬-glucosidase, the Defective Enzyme in Gaucher Disease Biological Crystallography Structural Comparison of Differently Glycosylated Forms of Acid-b-glucosidase, the Defective Enzyme in Gauch

  year unknowncited by this paper

• Synthesis of multimeric pyrrolidine iminosugar inhibitors of human β-glucocerebrosidase and α-galactosidase A: First example of a multivalent enzyme activity enhancer for Fabry disease.

  2020cites this paper
• Exploring substituent diversity on pyrrolidine-aryltriazole iminosugars: Structural basis of β-glucocerebrosidase inhibition.

  2019cites this paper
• Stereodivergent synthesis of right- and left-handed iminoxylitol heterodimers and monomers. Study of their impact on β-glucocerebrosidase activity.

  2017cites this paper
• Investigation of original multivalent iminosugars as pharmacological chaperones for the treatment of Gaucher disease.

  2016cites this paper
• New Directions in Gaucher Disease

  2016cites this paper
• Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.

  2016cites this paper
• Prenatal Diagnosis of Disorders of Lipid Metabolism

  2015cites this paper